Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy

Table 4 Effectiveness of 12-week adalimumab treatment in patients with PsA stratified by prior anti-TNF therapy

Outcome measure	No prior ETN/IFX	Prior ETN or IFX or both
	(n = 376)	(n = 66)
TJC (0 to 78)
Baseline	16	15
	10, 27	8, 25
Change, Baseline to week 12	-10	-10
	-17, -5	-16, -3
SJC (0 to 76)
Baseline	9	7
	5, 13	5, 11
Change, Baseline to week 12	-7	-5
	-10, -3	-8, -3
HAQ DI (0 to 3)
Baseline	1.25	1.44
	0.75, 1.63	1.00, 1.75
Change, Baseline to week 12	-0.50	-0.50
	-0.88, -0.13	-0.75, -0.25
Patients with nail psoriasis (NAPSI ≥ 1)	n = 223	n = 36
NAPSI (0 to 80)
Baseline	14	18
	5, 30	10, 37
Change, Baseline to week 12	-6	-6
	-14, -2	-15, -1

Values are expressed as median and quartile 1, quartile 3. ETN, etanercept; HAQ DI, Health Assessment Questionnaire Disability Index; IFX, infliximab; NAPSI, Nail Psoriasis Severity Index (only fingernails); PsA, psoriatic arthritis; SJC, swollen joint count; TJC, tender joint count; TNF, tumor necrosis factor.

ISSN: 1478-6362